AACE Releases New 2022 Diabetes Management Guidelines

Published on: 

The American Academy of Clinical Endocrinology (AACE) has released a new clinical practice guideline for the management of diabetes.

Announced on September 27, the new guideline, which represents the organization’s first update to the guideline recommendations for diabetes management since 2015, includes 170 updated and new evidence-based recommendations aimed at optimal management of diabetes at every stage, including prevention, diagnosis, and treatment.

“The updated diabetes guideline—created by clinicians, for clinicians—can be used by the multi-disciplinary care teams that are involved in the care and management of diabetes,” said S. Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, president of AACE and an author of the guideline, in a statement from the AACE. “The guideline is framed to support person-centered, team-based clinical decision-making, which importantly puts the patient at the center to improve care for people with prediabetes and diabetes.”

At pages in length and citing more than reference documents, the AACE’s updated guideline for management of diabetes was composed by Reddy and a team of more than 2 dozen leading experts in endocrinology and cardiometabolic health, including co-chairs Lawrence Blonde, MD, and Guillermo Umpierrez, MD. A reflection of the changing landscape of diabetes management, the guideline includes evidence-based recommendations on multiple new topics related to diabetes management, including COVID-19 vaccination, telehealth, infertility, secondary diabetes, nutritional supplements, and social determinants of health.

Leveraging data from the literature searches used to back recommendations in the 2015 guidelines on diabetes management and data from a more recent literature search, the new guideline’s recommendations were divided in 4 distinct sections:

  • Screening, diagnosis, glycemic targets, and glycemic monitoring
  • Comorbidities and complications
  • Management of prediabetes, type 2 diabetes with antihyperglycemic pharmacotherapy and glycemic targets, type 1 diabetes with insulin therapy, hypoglycemia, hospitalized persons, and women with diabetes in pregnancy
  • Education and new topics

Specific portions of the new guideline highlighted with the AACE’s aforementioned statement included information on the latest cardiovascular outcomes trial, perspective on FDA-approved weight loss medications and trends in management of obesity, and recommendations for management of comorbidites, including obesity, dyslipidemia, chronic kidney disease, and more. Additionally, throughout the guideline is an emphasis on the importance of a team-based approach for clinical decision-making in the management of diabetes, with the person with diabetes at the center of this team.

The AACE also pointed out the guideline will be discussed during in-person sessions at the organization's Cardiometabolic Conference, which is slated to occur from September 30-October 2, 2022 in San Antonio, TX.

This guideline, "American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update,” was published in Endocrine Practice.